000168307 001__ 168307
000168307 005__ 20240229133604.0
000168307 0247_ $$2doi$$a10.21873/anticanres.14957
000168307 0247_ $$2pmid$$apmid:33813396
000168307 0247_ $$2ISSN$$a0250-7005
000168307 0247_ $$2ISSN$$a1791-7530
000168307 0247_ $$2altmetric$$aaltmetric:106751683
000168307 037__ $$aDKFZ-2021-00818
000168307 041__ $$aEnglish
000168307 082__ $$a610
000168307 1001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b0$$eFirst author$$udkfz
000168307 245__ $$aHypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge.
000168307 260__ $$aAttiki$$c2021
000168307 3367_ $$2DRIVER$$aarticle
000168307 3367_ $$2DataCite$$aOutput Types/Journal article
000168307 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1618987721_5527
000168307 3367_ $$2BibTeX$$aARTICLE
000168307 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168307 3367_ $$00$$2EndNote$$aJournal Article
000168307 500__ $$a#EA:E055#
000168307 520__ $$aThis comparative plan study examines a range of boost-radiation methods in adjuvant radiotherapy of breast cancer using helical intensity-modulated radiotherapy with TomoEdge-technique. Impact of hypofractionated radiation with simultaneous-integrated boost (SIB) and influence of differing assumed α/β-values were examined.For 10 patients with left-sided breast cancer each four helical IMRT-plans with TomoEdge-technique were created: hypofractionated+SIB (H-SIB) (42.4/54.4 Gy, 16 fractions), normofractionated+SIB (N-SIB) (50.4/64.4 Gy, 28 fractions), hypofractionated+sequential-boost (H-SB) (42.4 Gy/16 fractions+16 Gy/8 fractions), normofractionated+ sequential-boost (N-SB) (50.4 Gy/28 fractions+16 Gy/8 fractions). Equivalent doses (EQD2) to organs-at-risk (OAR) and irradiated mammary-gland were analysed for different assumed α/β-values.The mean EQD2 to OAR was significantly lower using hypofractionated radiation-techniques. H-SIB and H-SB were not significantly different. H-SIB and N-SIB conformed significantly better to the breast planning-target volume (PTV) and boost-volume (BV) than H-SB and N-SB. Regarding BV, mean EQD2 was significantly higher for all α/β-values investigated when using H-SIB and N-SIB. Regarding PTV, there were no clinically relevant differences.Relating to dosimetry, H-SIB is effective compared to standard-boost-techniques.
000168307 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168307 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168307 650_7 $$2Other$$aHypofractionated radiotherapy
000168307 650_7 $$2Other$$aIMRT
000168307 650_7 $$2Other$$aSIB
000168307 650_7 $$2Other$$aTomoEdge
000168307 650_7 $$2Other$$abreast cancer
000168307 650_7 $$2Other$$ahelical tomotherapy
000168307 650_7 $$2Other$$asimultaneous integrated boost
000168307 7001_ $$aHoefel, Sebastian$$b1
000168307 7001_ $$aKirchner, Corinna$$b2
000168307 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b3$$udkfz
000168307 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b4
000168307 7001_ $$aSchempp, Michael$$b5
000168307 773__ $$0PERI:(DE-600)2145376-7$$a10.21873/anticanres.14957$$gVol. 41, no. 4, p. 1909 - 1920$$n4$$p1909 - 1920$$tAnticancer research$$v41$$x1791-7530$$y2021
000168307 909CO $$ooai:inrepo02.dkfz.de:168307$$pVDB
000168307 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168307 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168307 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000168307 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000168307 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168307 9141_ $$y2021
000168307 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTICANCER RES : 2019$$d2021-01-31
000168307 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-31
000168307 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x0
000168307 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000168307 980__ $$ajournal
000168307 980__ $$aVDB
000168307 980__ $$aI:(DE-He78)E055-20160331
000168307 980__ $$aI:(DE-He78)E050-20160331
000168307 980__ $$aUNRESTRICTED